PARP inhibitors

You have access
Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study
ANGIOLO GADDUCCI, STEFANIA COSIO, FABIO LANDONI, ANDREA ALBERTO LISSONI, PAOLO ZOLA, MARIA ELENA LAUDANI, ANTONIO ARDIZZOIA, ANGELA GAMBINO and ENRICO SARTORI

Anticancer Research April 2022, 42 (4) 2017-2022; DOI: https://doi.org/10.21873/anticanres.15681
You have access
PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review
CAIO BEZERRA MACHADO, EMERSON LUCENA DA SILVA, MANOEL ODORICO DE MORAES FILHO, MARIA ELISABETE AMARAL DE MORAES and CAROLINE AQUINO MOREIRA-NUNES

Anticancer Research June 2020, 40 (6) 3055-3063; DOI: https://doi.org/10.21873/anticanres.14286
You have access
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research
ANGIOLO GADDUCCI and MARIA ELENA GUERRIERI

Anticancer Research May 2016, 36 (5) 2055-2064;
You have access
Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now?
JOHN SYRIOS, SUSANA BANERJEE and STANLEY B. KAYE

Anticancer Research May 2014, 34 (5) 2069-2077;
You have access
Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines
EWA JASEK, MARIUSZ GAJDA, GRZEGORZ J. LIS, MAŁGORZATA JASIŃSKA and JAN A. LITWIN

Anticancer Research April 2014, 34 (4) 1849-1856;
You have access
‘BRCAness’ and Its Implications for Platinum Action in Gynecologic Cancer
FRANCO MUGGIA and TAMAR SAFRA

Anticancer Research February 2014, 34 (2) 551-556;

Main menu

User menu

Search

PARP inhibitors